Back to Search
Start Over
Dabigatran activates inflammation resolution by promoting fibrinogen-like protein 2 shedding and RvD5 n-3 DPA production.
- Source :
-
Theranostics [Theranostics] 2021 Feb 20; Vol. 11 (9), pp. 4251-4261. Date of Electronic Publication: 2021 Feb 20 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- Rationale: The interaction between coagulation and inflammation resolution remains elusive. We recently highlighted a link between fibrinogen-like protein 2 (Fgl2) and a specialized pro-resolving mediator (SPM)-n-3 docosapentaenoic acid-derived resolvin D5 (RvD5 <subscript>n-3 DPA</subscript> ) in sepsis. This study aimed to investigate the functions of commonly used anticoagulants warfarin, dabigatran and heparin in regulating inflammation resolution. Methods: Peripheral blood was collected from clinical sepsis patients and healthy control for the determination of indicated indexes. Mouse sepsis models of zymosan-induced peritonitis and cecal ligation and puncture (CLP) were employed for the measurement of inflammation- and coagulation-related indexes. Western-blotting, ELISA and flow cytometry were applied to assess proteins. UPLC-MS/MS was used to evaluate lipid metabolites. Results: Here we report that the transmembrane Fgl2 (mFgl2) was positively associated with coagulation, while soluble Fgl2 (sFgl2) level correlated with the enhanced number of peripheral blood mononuclear cells in the sepsis patients. The anticoagulants dabigatran and warfarin attenuated zymosan-induced peritonitis, which was not shared by heparin, while only dabigatran significantly improved sepsis survival in the CLP sepsis mouse model. Although these anticoagulants consistently inhibited pro-inflammatory mediators including prostaglandin E <subscript>2</subscript> and leukotriene B <subscript>4</subscript> , only dabigatran increased sFgl2 at both the initiation and resolution phases of inflammation. Mechanistically, dabigatran elicited the shedding of sFgl2 via prothrombin-related metalloproteases, thereby enhanced the subsequent biosynthesis of RvD5 <subscript>n-3 DPA</subscript> via STAT6-ALOX15 axis. Blocking metalloproteases or ALOX15 significantly impaired dabigatran-enhanced macrophage efferocytosis in vitro , as well as delayed the dabigatran-accelerated inflammation resolution in vivo . Conclusions: Our findings identify the dual anti-inflammatory and pro-resolving actions of dabigatran, through promoting sFgl2-triggered RvD5 <subscript>n-3 DPA</subscript> production, which has important implications for promoting tissue homeostasis of sepsis.<br />Competing Interests: Competing Interests: The authors have declared that no competing interest exists.<br /> (© The author(s).)
- Subjects :
- Animals
Anticoagulants pharmacology
Chromatography, Liquid methods
Disease Models, Animal
Humans
Inflammation drug therapy
Inflammation Mediators metabolism
Leukocytes, Mononuclear drug effects
Leukocytes, Mononuclear metabolism
Macrophages drug effects
Macrophages metabolism
Male
Metalloproteases metabolism
Mice
Mice, Inbred C57BL
Prothrombin metabolism
Sepsis drug therapy
Sepsis metabolism
Tandem Mass Spectrometry methods
Zymosan pharmacology
Dabigatran pharmacology
Docosahexaenoic Acids metabolism
Fatty Acids, Unsaturated metabolism
Fibrinogen metabolism
Inflammation metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1838-7640
- Volume :
- 11
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Theranostics
- Publication Type :
- Academic Journal
- Accession number :
- 33754059
- Full Text :
- https://doi.org/10.7150/thno.50182